Disease-free survival following high dose or standard dose therapy in patients with amyloidosis

Br J Haematol. 2016 Jul;174(1):153-5. doi: 10.1111/bjh.13656. Epub 2015 Aug 28.

Authors

Patrick J Kiel¹, Anne O Trueg², Meagan Ferguson², Merrill Benson³, Rafat Abonour³

Affiliations

¹ Department of Pharmacy, Indiana University Health Simon Cancer Center, Indianapolis, IN, USA. pkiel@iuhealth.org.
² Department of Pharmacy, Indiana University Health Simon Cancer Center, Indianapolis, IN, USA.
³ Indiana University School of Medicine, Indianapolis, IN, USA.

PMID: 26314806
DOI: 10.1111/bjh.13656

No abstract available

Keywords: autologous haematopoietic cell rescue; bortezomib; melphalan; treatment related mortality.

Publication types

Comparative Study
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Amyloidosis / drug therapy
Amyloidosis / mortality*
Amyloidosis / therapy
Bortezomib / therapeutic use
Disease-Free Survival
Hematopoietic Stem Cell Transplantation / methods
Hematopoietic Stem Cell Transplantation / mortality
Humans
Melphalan / therapeutic use
Middle Aged
Retrospective Studies
Transplantation, Autologous
Treatment Outcome

Substances

Bortezomib
Melphalan